Cargando…
Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products()
Several companies were authorized to treat COVID-19 patients with monoclonal antibodies within 1–2 years of the start of the pandemic. These products were discovered, developed, manufactured, clinically tested, and approved under emergency-use authorization at unprecedented speed. Pandemic urgency l...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436891/ https://www.ncbi.nlm.nih.gov/pubmed/36179406 http://dx.doi.org/10.1016/j.copbio.2022.102798 |
_version_ | 1784781474508046336 |
---|---|
author | Kelley, Brian De Moor, Pam Douglas, Kristen Renshaw, Todd Traviglia, Stacey |
author_facet | Kelley, Brian De Moor, Pam Douglas, Kristen Renshaw, Todd Traviglia, Stacey |
author_sort | Kelley, Brian |
collection | PubMed |
description | Several companies were authorized to treat COVID-19 patients with monoclonal antibodies within 1–2 years of the start of the pandemic. These products were discovered, developed, manufactured, clinically tested, and approved under emergency-use authorization at unprecedented speed. Pandemic urgency led to novel development approaches that reduced the time to clinical trials by 75% or more without creating unacceptable patient or product-safety risks. Hundreds of thousands of patients now benefit from these therapeutics that have reduced the rates of hospitalization and death. The chemistry, manufacturing, and control development strategies set a new precedent of speed, safety, and demonstrated clinical benefit and will likely have a lasting impact on the development of future monoclonal antibody therapies for not only infectious diseases but also for oncology, inflammation, and rare diseases. |
format | Online Article Text |
id | pubmed-9436891 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94368912022-09-02 Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products() Kelley, Brian De Moor, Pam Douglas, Kristen Renshaw, Todd Traviglia, Stacey Curr Opin Biotechnol Article Several companies were authorized to treat COVID-19 patients with monoclonal antibodies within 1–2 years of the start of the pandemic. These products were discovered, developed, manufactured, clinically tested, and approved under emergency-use authorization at unprecedented speed. Pandemic urgency led to novel development approaches that reduced the time to clinical trials by 75% or more without creating unacceptable patient or product-safety risks. Hundreds of thousands of patients now benefit from these therapeutics that have reduced the rates of hospitalization and death. The chemistry, manufacturing, and control development strategies set a new precedent of speed, safety, and demonstrated clinical benefit and will likely have a lasting impact on the development of future monoclonal antibody therapies for not only infectious diseases but also for oncology, inflammation, and rare diseases. Elsevier Ltd. 2022-12 2022-09-02 /pmc/articles/PMC9436891/ /pubmed/36179406 http://dx.doi.org/10.1016/j.copbio.2022.102798 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Kelley, Brian De Moor, Pam Douglas, Kristen Renshaw, Todd Traviglia, Stacey Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products() |
title | Monoclonal antibody therapies for COVID-19: lessons learned
and implications for the development of future products() |
title_full | Monoclonal antibody therapies for COVID-19: lessons learned
and implications for the development of future products() |
title_fullStr | Monoclonal antibody therapies for COVID-19: lessons learned
and implications for the development of future products() |
title_full_unstemmed | Monoclonal antibody therapies for COVID-19: lessons learned
and implications for the development of future products() |
title_short | Monoclonal antibody therapies for COVID-19: lessons learned
and implications for the development of future products() |
title_sort | monoclonal antibody therapies for covid-19: lessons learned
and implications for the development of future products() |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436891/ https://www.ncbi.nlm.nih.gov/pubmed/36179406 http://dx.doi.org/10.1016/j.copbio.2022.102798 |
work_keys_str_mv | AT kelleybrian monoclonalantibodytherapiesforcovid19lessonslearnedandimplicationsforthedevelopmentoffutureproducts AT demoorpam monoclonalantibodytherapiesforcovid19lessonslearnedandimplicationsforthedevelopmentoffutureproducts AT douglaskristen monoclonalantibodytherapiesforcovid19lessonslearnedandimplicationsforthedevelopmentoffutureproducts AT renshawtodd monoclonalantibodytherapiesforcovid19lessonslearnedandimplicationsforthedevelopmentoffutureproducts AT travigliastacey monoclonalantibodytherapiesforcovid19lessonslearnedandimplicationsforthedevelopmentoffutureproducts |